Association between advanced glycation end products (AGEs) and diabetic complications: A systematic review and meta-analysis.
Anditri Weningtyas, Victor Alvianoes Guterez Hose, Dian Nugrahenny et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the association between advanced glycation end products (AGEs) and diabetic complications in 6,288 participants across 15 studies. The analysis found that patients with complications had significantly higher AGE levels compared to those without, with a pooled mean difference of 0.29 AU. Tissue-bound AGEs were consistently elevated in both microvascular and macrovascular complications.
Key findings
- Patients with complications had significantly higher AGE levels than those without, with a pooled mean difference of 0.29 AU.
- Tissue-bound AGEs via skin autofluorescence were elevated across all microvascular and macrovascular subtypes.
- Circulating CML showed a robust association with macrovascular outcomes, with a mean difference of 20.24 µmol/mol lys.
Why it matters
Understanding the role of AGEs in diabetic complications can help clinicians identify patients at higher risk for vascular issues. Elevated AGEs may serve as important biomarkers for monitoring and managing diabetes-related complications.